Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

and Imfinzi (durvalumab) in NHS patients across England and Wales. Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab ... standard-of-care chemoradiation followed by consolidation Imfinzi ...

The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi (durvalumab).

and Imfinzi (durvalumab), within England and Wales’s National Health Service (NHS). Tagrisso has been recommended as an ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.